{"id":"W2050501917","doi":"10.1111/jdv.12996","title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","year":2015,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Plaque psoriasis; Dermatology; Scalp; Psoriasis; Nail (fastener); Psoriatic arthritis; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003097705,0.00138921,0.00240099,0.0003803924,0.0003291696,0.0008872388,0.0005778601,0.001147386,0.003212319],"category_scores_gemma":[0.001958118,0.0005911568,0.001680047,0.0003191528,0.0007702745,0.0007387411,0.0003528925,0.002061496,0.000469878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005326749,"about_ca_system_score_gemma":0.001054669,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006516268,"about_ca_topic_score_gemma":0.001300443,"domain_scores_codex":[0.9990855,0.0005582557,0.00004919169,0.000114051,0.00006942488,0.000123465],"domain_scores_gemma":[0.9989454,0.0003411611,0.0002426186,0.00009242178,0.00007789564,0.0003005429],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9566158,0.01047116,0.001931427,0.0004677548,0.0006504607,0.00007325707,0.00009587601,0.0003403926,0.005457133,0.00005633841,0.0004727561,0.02336762],"study_design_scores_gemma":[0.8885025,0.1053059,0.004848704,0.00002317103,0.0002741589,0.00004963124,0.00002027607,0.0002501447,0.0003506504,0.00005213148,0.000314023,0.000008640958],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948895,0.002175496,0.0002026528,0.0002561705,0.0001028303,0.001328902,0.0002808371,0.00004198657,0.0007215771],"genre_scores_gemma":[0.991423,0.002126231,0.001073957,0.0004795668,0.0002959678,0.002512952,0.0007470495,0.00001395226,0.001327362],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003212319,"threshold_uncertainty_score":0.0163824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0179566252867597,"score_gpt":0.2474452385717072,"score_spread":0.2294886132849475,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}